Ahn Mi Young, Kim Ban Ji, Yoon Hyung Joo, Hwang Jae Sam, Park Kun-Koo
Department of Agricultural Biology, National Academy of Agricultural Science, RDA, Wanju, Korea.
Pharmacogenechips Inc., Chuncheon, Korea.
Toxicol Res. 2018 Apr;34(2):151-162. doi: 10.5487/TR.2018.34.2.151. Epub 2018 Apr 15.
Anti-diabetes activity of (Ca, a type of dung beetle) glycosaminoglycan (G) was evaluated to reduce glucose, creatinine kinase, triglyceride and free fatty acid levels in db mice. Diabetic mice in six groups were administrated intraperitoneally: Db heterozygous (Normal), Db homozygous (CON), glycosaminoglycan (HEG, 5 mg/kg), dung beetle glycosaminoglycan (CaG, 5 mg/kg), bumblebee () queen glycosaminoglycan (IQG, 5 mg/kg) and metformin (10 mg/kg), for 1 month. Biochemical analyses in the serum were evaluated to determine their anti-diabetic and anti-inflammatory actions in db mice after 1 month treatment with HEG, CaG or IQG treatments. Blood glucose level was decreased by treatment with CaG. CaG produced significant anti-diabetic actions by inhiting creatinine kinase and alkaline phosphatase levels. As diabetic parameters, serum glucose level, total cholesterol and triglyceride were significantly decreased in CaG5-treated group compared to the controls. Dung beetle glycosaminoglycan, compared to the control, could be a potential therapeutic agent with anti-diabetic activity in diabetic mice. CaG5-treated group, compared to the control, showed the up-regulation of 48 genes including mitochondrial yen coded tRNA lysine (mt-TK), cytochrome P450, family 8/2, subfamily b, polypeptide 1 (Cyp8b1), and down-regulation of 79 genes including S100 calcium binding protein A9 (S100a9) and immunoglobulin kappa chain complex (Igk), and 3-hydroxy-3-methylglutaryl-CoenzymeAsynthase1 (Hmgcs1). Moreover, mitochondrial thymidine kinase (mt-TK), was up-regulated, and calgranulin A (S100a9) were down-regulated by CaG5 treatment, indicating a potential therapeutic use for anti-diabetic agent.
评估粪金龟（一种蜣螂）糖胺聚糖（G）的抗糖尿病活性，以降低db小鼠的血糖、肌酸激酶、甘油三酯和游离脂肪酸水平。将六组糖尿病小鼠进行腹腔注射给药：db杂合子（正常）、db纯合子（对照）、糖胺聚糖（HEG，5mg/kg）、粪金龟糖胺聚糖（CaG，5mg/kg）、大黄蜂蜂王糖胺聚糖（IQG，5mg/kg）和二甲双胍（10mg/kg），持续1个月。在使用HEG、CaG或IQG治疗1个月后，对血清进行生化分析，以确定它们在db小鼠中的抗糖尿病和抗炎作用。用CaG治疗可降低血糖水平。CaG通过抑制肌酸激酶和碱性磷酸酶水平产生显著的抗糖尿病作用。作为糖尿病参数，与对照组相比，CaG5治疗组的血清葡萄糖水平、总胆固醇和甘油三酯显著降低。与对照组相比，粪金龟糖胺聚糖可能是糖尿病小鼠中具有抗糖尿病活性的潜在治疗剂。与对照组相比，CaG5治疗组显示48个基因上调，包括线粒体编码的赖氨酸tRNA（mt-TK）、细胞色素P450家族8/2亚家族b多肽1（Cyp8b1），79个基因下调，包括S100钙结合蛋白A9（S100a9）和免疫球蛋白κ链复合物（Igk），以及3-羟基-3-甲基戊二酰辅酶A合酶1（Hmgcs1）。此外，CaG5处理使线粒体胸苷激酶（mt-TK）上调，钙粒蛋白A（S100a9）下调，表明其作为抗糖尿病药物具有潜在的治疗用途。
